The world’s biggest stablecoins are increasingly becoming chain-specific financial products, with Tether’s USDt (USDT) and Circle’s USDC (USDC) serving distinct roles across the crypto ecosystem rather than competing head-on.

Dune’s Digital Asset Brief found that USDT overwhelmingly dominates onchain payments. During the first half of 2026, the biggest stablecoin settled about $95 billion in identified commerce payments, compared with $14 billion for second-biggest USDC. It also accounted for roughly 92% of the $48 billion in business-to-business payment volume. On Tron, USDT’s largest network, around 93% of the token’s supply is held in ordinary wallets rather than on exchanges, underscoring its role as a payment and remittance asset.

USDC, meanwhile, has established itself as the dominant stablecoin in decentralized finance. USDC on Base processed roughly $2.6 trillion in transfer volume in June, the highest of any token-chain pair, while on Ethereum, that stablecoin handled another $1.6 trillion. 

USDC on Base recorded daily velocity of about 20 times its circulating supply in June, reflecting its extensive use in trading and DeFi. Source: Dune

The findings suggest the traditional USDT-versus-USDC narrative is becoming less useful. Instead, each stablecoin is carving out its own niche, with USDT dominating payments and USDC underpinning much of crypto’s trading and DeFi activity.

USDT’s supply is split almost evenly between Tron and Ethereum, while USDC remains heavily concentrated on Ethereum despite expanding to newer blockchains. Source: Dune

The findings come as the two digital assets continue to dominate the stablecoin market. Together, they account for roughly 83% of the sector’s approximately $315 billion market capitalization, according to Dune, which tracked more than 200 stablecoin tokens across multiple blockchains.

Related: UN agency moves Stellar blockchain payment initiative beyond pilot stage

US lawmakers reshape stablecoin rules

The stablecoin sector has gained momentum in the United States following the passage of the GENIUS Act. Signed into law in 2025, GENIUS established the first federal regulatory framework for payment stablecoins, paving the way for banks and other companies to issue US dollar-pegged digital assets.

Lawmakers are now debating the CLARITY Act, which would establish a broader market structure for digital assets by defining when crypto assets fall under the jurisdiction of the US Securities and Exchange Commission or the US Commodity Futures Trading Commission. While the bill does not regulate stablecoins directly, it would shape the broader regulatory environment in which stablecoin issuers, exchanges and DeFi platforms operate.

CLARITY cleared the Senate Banking Committee in May and could receive a full Senate vote before the August recess, although Galaxy recently trimmed its odds of passage before the break to 50% as lawmakers run short on time.

Magazine: Kraken’s $600M stablecoin firm, Huione scandal deepens: Asia Express

Key Highlights

• STLA experiences decline as FIAT announces Topolino pre-orders launching July 2026.
• Compact Topolino model targets city-based transportation and brief neighborhood commutes.
• Stellantis broadens portfolio beyond conventional automobiles into micromobility sector.
• Urban convenience drives FIAT’s strategy with small-format vehicle design.
• Topolino represents fresh U.S. micromobility alternative in Stellantis brand family.

Shares of Stellantis declined 1.29% to $5.73 as FIAT announced its plan to begin accepting U.S. pre-orders for the Topolino starting July 2026. This move represents the automaker’s strategic shift toward micromobility solutions. The initiative positions FIAT within the emerging compact neighborhood transportation market.

Stellantis N.V., STLA

FIAT Launches Topolino for American Consumers

The Italian brand plans to offer the Topolino as a micro-vehicle solution tailored for American buyers. This model emphasizes brief journeys, crowded urban environments, and customers prioritizing straightforward transportation. It incorporates FIAT’s signature Italian styling within a miniature vehicle format.

While the Topolino projects a whimsical aesthetic, FIAT markets it as functional urban infrastructure. Its compact dimensions facilitate simplified parking and reduced operational complexity. Consequently, the vehicle addresses increasing consumer interest in localized mobility solutions.

According to company announcements, U.S. customers can begin placing orders in July 2026. FIAT enters a market segment defined by accessibility and metropolitan functionality. This introduction provides Stellantis with an additional pathway into the compact transportation arena.

Stellantis Broadens Mobility Portfolio

Stellantis leverages the Topolino introduction to diversify beyond conventional passenger automobiles. The conglomerate currently oversees numerous brands spanning diverse international territories. Accordingly, the Topolino addresses a niche for abbreviated daily transportation requirements.

Micromobility solutions have attracted significant interest as metropolitan areas reconsider congestion, affordability, and accessibility. Compact vehicles serve localized travel without substituting full-sized automobiles. FIAT’s market entry acknowledges this transformation and enhances overall product adaptability.

The Topolino reinforces FIAT’s distinctive character within the Stellantis brand ecosystem. Its aesthetic honors the marque’s historical legacy while fulfilling contemporary mobility demands. Nevertheless, consumer acceptance hinges on affordability, availability, and regulatory frameworks.

FIAT Introduces Specialized Metropolitan Solution

STLA experienced weakness during morning sessions before recovering modestly at midday. This movement coincided with Stellantis announcing its fresh U.S. product initiative. Individual product debuts seldom influence immediate market perception significantly.

The Topolino establishes FIAT within the specialized compact urban transportation category. It facilitates daily mobility across residential areas, educational facilities, and brief metropolitan routes. Thus, the vehicle may attract consumers beyond conventional automotive segments.

Stellantis now incorporates the Topolino into its American mobility strategy. The model provides FIAT with a unique position within an expanding transportation sector. Meanwhile, the corporation’s overall success depends on comprehensive portfolio execution.

As of 8:19am today in New York, every retail investor who had ever bought shares of Enlivex on the Nasdaq, an arthritis biotech-turned-digital asset treasury (DAT), had lost money.

The company bet its balance sheet on the RAIN crypto token that ZachXBT eventually tied to Moshe Hogeg, an Israeli entrepreneur facing a $290 million law enforcement investigation.

Shares of Enlivex, which have been trading publicly for 12 years, traded to their all-time low of $0.42 this morning. Investors are slowly losing it all.

Hogeg has denied fraud allegations via a spokesperson.

The biotech company spent years developing clinical therapeutics. Bizarrely, it then reinvented itself in November 2025 to what it called the “world’s first prediction markets digital asset treasury strategy.”

That was a world first — and probably last.

The company raised over $200 million through a private placement at $1 per share, funded in dollars and USDT.

It also apppointed a former prime minister of Italy to its board, and spent money accumulating RAIN, a so-called governance token of an Arbitrum-based protocol, calling it “the Uniswap of prediction markets.” 

Still today, Enlivex holds about 78.8 billion RAIN worth $1.2 billion, equal to 12% of the token’s circulating supply.

Sadly, even though the token has independently rallied substantially since last year, shares of its largest publicly traded holding company keep falling.

Something is wrong at that company.

UK Reform Party leader Nigel Farage has announced he will resign as the Member of Parliament for Clacton and stand in the by-election that could determine whether he remains in the job. Farage said his decision follows what he described as “foul means” used by established politicians, after reports that he received gifts and donations linked to crypto figures and a convicted fraudster.

His move comes amid parliamentary standards scrutiny of the circumstances around those reported transfers. Farage has repeatedly insisted he has done nothing wrong and says the upcoming contest should give voters a direct say on his actions.

Key takeaways

• Farage confirmed he will resign as MP for Clacton and run in the resulting by-election, framing it as a decision for voters rather than a legal verdict.
• Reports cited by UK coverage link alleged gifts to crypto billionaire Christopher Harborne and George Cottrell, a convicted fraudster associated with a crypto casino.
• Farage said he is the subject of two probes by the UK parliamentary standards commissioner.
• Farage has long had ties to the crypto industry, including speaking at Bitcoin 2025 in Las Vegas and being an investor in a London-listed “Bitcoin treasury” company, Stack.
• The UK case lands as US elections approach, with watchdog reporting continued spending by crypto industry groups to influence candidate outcomes.

Farage steps aside from Clacton seat amid standards probe

Farage made the announcement in a Tuesday statement on X. He said he would resign as MP representing Clacton, followed by the formal by-election process. In his message, Farage argued that he has not broken any law or misused public funds, while also pointing to what he described as unfair tactics by political opponents.

According to reporting referenced by Cointelegraph, the renewed attention began after allegations that Farage received millions of dollars’ worth of donations and gifts connected to Christopher Harborne and George Cottrell. The original claims have been discussed alongside an investigation into UK parliamentary standards, with scrutiny focused on whether the nature and receipt of those benefits complied with rules governing MPs.

“Let me be absolutely clear: I have done nothing wrong,” Farage said in an X livestream. “I have not broken the law in any way at all. I have not misused public money.”

What Farage says about the gifts—and why the by-election matters

Farage confirmed he is facing two probes by the UK parliamentary standards commissioner. In comments relayed through the same coverage, he described the reported gifts as being provided “on an unconditional basis.”

He also said he planned to use Harborne’s gift specifically for funding related to his security, citing ongoing threats and attacks. In a separate passage explaining his decision, Farage suggested the by-election would allow constituents to judge whether he should continue representing them.

“I’ve decided that the people of Clacton should be the judges of my actions […] I will be putting my name forward to stand in this by-election.”

Coverage from the London Standard indicated that the by-election outcome could take weeks or months to resolve, largely due to the logistics of stepping down and calling the vote. Farage previously won the Clacton seat with 46.2% of the vote in July 2024, according to the same reporting, edging out Conservative and Labour candidates.

Crypto links predate the current controversy

Cointelegraph reported that Farage had connections to the crypto sector well before the latest set of allegations. That includes his appearance at Bitcoin 2025 in Las Vegas and his role as an investor in Stack, described in earlier coverage as a London-listed Bitcoin treasury company.

In May, when reports first circulated about a claimed $6.7 million “gift” from Christopher Harborne, Farage described it as a “reward” for campaigning for Brexit—the 2016 referendum that led to the UK’s exit from the European Union. Those earlier remarks help explain why the current dispute is not only about alleged donations, but also about how Farage has sought to characterize his relationships with crypto-linked donors.

The latest developments also broaden the conversation beyond crypto money alone. The reported involvement of George Cottrell—described in the cited coverage as a convicted fraudster linked to a crypto casino—adds an additional compliance and reputational dimension that could intensify the scrutiny of how political figures accept benefits and whether disclosure obligations were met.

Pressure on crypto-linked politics extends to the US

While Farage faces UK scrutiny, the question of whether crypto-linked funding can shape elections is not confined to the UK. As November approaches for the US midterms, consumer advocacy group Public Citizen reported in June that the crypto industry spent about $189 million to support candidates viewed as favorable to digital asset policies as part of the 2026 election cycle.

That same broader political backdrop includes criticism directed at US President Donald Trump over his 2025 financial disclosures. Cointelegraph noted that Trump’s filings included reporting $1.4 billion in earnings related to crypto, which has drawn complaints from many lawmakers about possible conflicts and the transparency of his financial ties.

Taken together, the UK by-election dispute and the US election-cycle spending claims reflect a recurring political issue: how regulators, voters, and lawmakers assess the influence of digital asset wealth—especially when potential donors and campaign backers are tied to the industry itself.

What to watch next in Clacton

For voters in Clacton, the immediate variable is straightforward: whether Farage can retain support in the by-election even as parliamentary probes continue. For observers of crypto and politics, the key open question is how the standards commissioner’s findings—once available—will address the substance of Farage’s claims about the gifts, their “unconditional” nature, and what the process will ultimately mean for political fundraising scrutiny.

Key Takeaways

• Eli Lilly dominates the weight-loss and diabetes medication sector with Zepbound and Mounjaro, supported by robust research and development
• Abbott Laboratories offers balanced exposure through medical devices, laboratory diagnostics, and nutritional products
• Johnson & Johnson has streamlined operations around pharmaceuticals and medical technology following its consumer division spinoff
• These companies capitalize on demographic shifts and increasing healthcare consumption worldwide
• Market participants are shifting capital from overvalued tech equities toward stable healthcare investments in 2026

As 2026 unfolds, healthcare equities are capturing significant investor attention amid a broader rotation away from elevated technology valuations. Three pharmaceutical and medical device leaders stand out: Eli Lilly, Abbott Laboratories, and Johnson & Johnson.

Eli Lilly

Eli Lilly has emerged as a dominant force in modern pharmaceutical innovation.

Eli Lilly and Company, LLY

The Indianapolis-based giant commands the rapidly expanding obesity and diabetes therapeutic market with its blockbuster GLP-1 medications Zepbound and Mounjaro. Global appetite for these treatments shows no signs of slowing, with market researchers projecting sustained revenue expansion throughout the decade.

Wall Street firms including JPMorgan have maintained bullish ratings on the stock, citing accelerating Medicare coverage and sustained prescription growth for weight management therapies.

Lilly’s innovation extends far beyond metabolic health. The company maintains an impressive development portfolio spanning cancer treatments, neurological disorders, autoimmune conditions, and cardiometabolic diseases. Strategic acquisitions and substantial manufacturing investments position the firm for continued expansion.

While shares command elevated multiples, market analysts argue the premium pricing reflects exceptional earnings growth prospects within the pharmaceutical sector.

Abbott Laboratories

Abbott Laboratories operates with a distinctly different business model compared to traditional drug manufacturers.

Abbott Laboratories, ABT

This Chicago-based healthcare giant maintains operations across four major segments: medical devices, diagnostic products, nutritional supplements, and generic pharmaceuticals. This diversified structure has enabled consistent performance across varying market environments.

Abbott’s FreeStyle Libre continuous glucose monitoring system represents a breakthrough in diabetes management technology. Meanwhile, its cardiovascular device portfolio and diagnostic testing divisions benefit from global demographic trends and expanding healthcare access.

The company produces dependable free cash flow, funding both product innovation and a progressively increasing dividend payout.

Johnson & Johnson

Johnson & Johnson has refined its strategic direction following the separation of its consumer products division.

Johnson & Johnson, JNJ

The New Brunswick-based corporation now centers exclusively on prescription medicines and medical technology platforms. Its oncology franchise continues expanding, powered by robust demand for Darzalex. Following recent European regulatory clearance, the company is broadening its cancer therapy offerings ahead of quarterly financial disclosures.

Cardiovascular interventional devices and surgical equipment categories are posting solid advancement. Johnson & Johnson’s exceptional track record includes over 60 consecutive years of dividend increases, establishing it as a cornerstone holding for income-focused portfolios.

The Investment Case for This Healthcare Trio

Healthcare equities are attracting capital for compelling fundamental reasons. Demographic aging, escalating demand for breakthrough therapies, and promising pharmaceutical development pipelines collectively support sector momentum throughout 2026.

Eli Lilly represents the highest growth trajectory among the three. Abbott delivers portfolio diversification and operational consistency. Johnson & Johnson merges pharmaceutical innovation with an unmatched dividend growth history.

Collectively, these three holdings provide comprehensive exposure to prescription drugs, medical equipment, diagnostic testing, and resilient healthcare spending patterns.